HDAC and HDAC Inhibitors: Implication in Different Pathological Ailments

Authors

  • Priti Jain R C Patel Institute of Pharmaceutical Education and Research, Shirpur

Abstract

Histone deacetylases (HDAC) and its inhibitors have been found implicated in various diseased conditions. HDACs regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. They have also been found to regulate the post translational modifications through deacetylation of proteins, and hence are involved in many pathophysiological conditions. Till date, USFDA has approved vorinostat, romidepsin, panobinostat, and belinostat as HDAC inhibitors for the treatment of cancer. Considering their wide role in various diseases, more HDAC inhibitors are being developed for the treatment of other diseases such as Alzheimer’s disease, other neurodegenerative disorders, inflammatory diseases and cardiovascular disorders. This review deals with the role of HDCs in various physiological states, their involvement in different diseases and future implications therein.

 

Keywords: HDAC, SIRT, Cancer, Alzheimer, Huntingtons, Cardiac ischemia

 

Cite this Article

Priti Jain. HDAC and HDAC Inhibitors: Implication in Different Pathological Ailments. Research & Reviews: A Journal of Drug Design & Discovery. 2018; 5(3): 35–40p.

Downloads

Published

2019-01-16

Issue

Vol. 5 No. 3 (2018)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.